Anika Gross Profit from 2010 to 2024

ANIK Stock  USD 25.97  0.40  1.56%   
Anika Therapeutics Gross Profit yearly trend continues to be quite stable with very little volatility. Gross Profit may rise above about 108.2 M this year. Gross Profit is the profit Anika Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals
 
Gross Profit  
First Reported
1993-03-31
Previous Quarter
24.9 M
Current Value
26.3 M
Quarterly Volatility
8.8 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 1.2 M or Selling General Administrative of 103.5 M, as well as many exotic indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 310 or PTB Ratio of 1.73. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
This module can also supplement Anika Therapeutics' financial leverage analysis and stock options assessment as well as various Anika Therapeutics Technical models . Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Latest Anika Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Anika Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Anika Therapeutics minus its cost of goods sold. It is profit before Anika Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Anika Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 96.78 M10 Years Trend
Slightly volatile
   Gross Profit   
       Timeline  

Anika Gross Profit Regression Statistics

Arithmetic Mean71,467,497
Geometric Mean50,915,847
Coefficient Of Variation39.30
Mean Deviation20,710,794
Median79,352,000
Standard Deviation28,083,885
Sample Variance788.7T
Range107.9M
R-Value0.85
Mean Square Error230.8T
R-Squared0.73
Significance0.000052
Slope5,359,059
Total Sum of Squares11041.9T

Anika Gross Profit History

2024108.2 M
2023103.1 M
202293.6 M
202182.9 M
202069 M
201985.9 M
201874.3 M

Other Fundumenentals of Anika Therapeutics

Anika Therapeutics Gross Profit component correlations

0.98-0.60.950.510.60.580.890.310.410.680.860.640.420.60.760.16-0.12-0.08-0.660.36-0.34-0.04
0.98-0.720.980.420.560.420.950.180.490.70.870.640.40.470.810.2-0.13-0.17-0.710.38-0.21-0.09
-0.6-0.72-0.71-0.01-0.180.12-0.850.41-0.25-0.63-0.61-0.45-0.340.06-0.63-0.270.130.320.68-0.34-0.350.25
0.950.98-0.710.360.460.390.930.190.510.560.810.720.270.470.790.23-0.28-0.11-0.650.44-0.16-0.1
0.510.42-0.010.360.750.770.330.490.380.40.430.170.220.410.46-0.540.010.18-0.22-0.33-0.80.61
0.60.56-0.180.460.750.650.480.370.490.690.670.110.520.280.7-0.56-0.01-0.2-0.53-0.33-0.670.63
0.580.420.120.390.770.650.240.630.080.320.390.310.320.710.32-0.35-0.170.28-0.2-0.07-0.790.46
0.890.95-0.850.930.330.480.240.020.520.710.870.590.380.20.860.16-0.19-0.26-0.710.27-0.01-0.12
0.310.180.410.190.490.370.630.020.23-0.10.260.370.00.430.18-0.21-0.160.250.21-0.07-0.570.27
0.410.49-0.250.510.380.490.080.520.230.250.470.32-0.03-0.10.71-0.35-0.33-0.19-0.29-0.22-0.270.38
0.680.7-0.630.560.40.690.320.71-0.10.250.790.180.840.20.62-0.050.21-0.38-0.750.0-0.160.06
0.860.87-0.610.810.430.670.390.870.260.470.790.530.590.270.790.05-0.15-0.27-0.610.08-0.2-0.04
0.640.64-0.450.720.170.110.310.590.370.320.180.530.190.410.470.23-0.530.03-0.30.42-0.04-0.16
0.420.4-0.340.270.220.520.320.380.0-0.030.840.590.190.20.32-0.050.12-0.44-0.56-0.02-0.070.05
0.60.470.060.470.410.280.710.20.43-0.10.20.270.410.20.040.270.090.32-0.250.5-0.56-0.05
0.760.81-0.630.790.460.70.320.860.180.710.620.790.470.320.04-0.25-0.26-0.44-0.72-0.07-0.230.28
0.160.2-0.270.23-0.54-0.56-0.350.16-0.21-0.35-0.050.050.23-0.050.27-0.250.25-0.02-0.040.840.57-0.95
-0.12-0.130.13-0.280.01-0.01-0.17-0.19-0.16-0.330.21-0.15-0.530.120.09-0.260.25-0.18-0.120.04-0.04-0.25
-0.08-0.170.32-0.110.18-0.20.28-0.260.25-0.19-0.38-0.270.03-0.440.32-0.44-0.02-0.180.60.01-0.330.05
-0.66-0.710.68-0.65-0.22-0.53-0.2-0.710.21-0.29-0.75-0.61-0.3-0.56-0.25-0.72-0.04-0.120.6-0.180.1-0.03
0.360.38-0.340.44-0.33-0.33-0.070.27-0.07-0.220.00.080.42-0.020.5-0.070.840.040.01-0.180.38-0.65
-0.34-0.21-0.35-0.16-0.8-0.67-0.79-0.01-0.57-0.27-0.16-0.2-0.04-0.07-0.56-0.230.57-0.04-0.330.10.38-0.65
-0.04-0.090.25-0.10.610.630.46-0.120.270.380.06-0.04-0.160.05-0.050.28-0.95-0.250.05-0.03-0.65-0.65
Click cells to compare fundamentals

About Anika Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Anika Therapeutics income statement, its balance sheet, and the statement of cash flows. Anika Therapeutics investors use historical funamental indicators, such as Anika Therapeutics's Gross Profit, to determine how well the company is positioned to perform in the future. Although Anika Therapeutics investors may use each financial statement separately, they are all related. The changes in Anika Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Anika Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Anika Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Anika Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Gross Profit103.1 M108.2 M
Gross Profit Margin 0.62  0.45 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Anika Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Anika Therapeutics' short interest history, or implied volatility extrapolated from Anika Therapeutics options trading.

Pair Trading with Anika Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anika Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anika Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Anika Stock

  0.58ETON Eton Pharmaceuticals Financial Report 9th of May 2024 PairCorr
  0.56SBFMW Sunshine BiopharmaPairCorr
  0.54EVOK Evoke PharmaPairCorr
  0.48DVAX Dynavax Technologies Financial Report 7th of May 2024 PairCorr
The ability to find closely correlated positions to Anika Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anika Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anika Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anika Therapeutics to buy it.
The correlation of Anika Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anika Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Anika Stock analysis

When running Anika Therapeutics' price analysis, check to measure Anika Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anika Therapeutics is operating at the current time. Most of Anika Therapeutics' value examination focuses on studying past and present price action to predict the probability of Anika Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anika Therapeutics' price. Additionally, you may evaluate how the addition of Anika Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is Anika Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(5.64)
Revenue Per Share
11.372
Quarterly Revenue Growth
0.085
Return On Assets
(0.02)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.